WO1997014961A1 - Method of diagnosing malignant disorders - Google Patents
Method of diagnosing malignant disorders Download PDFInfo
- Publication number
- WO1997014961A1 WO1997014961A1 PCT/RU1995/000225 RU9500225W WO9714961A1 WO 1997014961 A1 WO1997014961 A1 WO 1997014961A1 RU 9500225 W RU9500225 W RU 9500225W WO 9714961 A1 WO9714961 A1 WO 9714961A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- κροvi
- analysis
- sπeκτρalny
- identifies
- chτο
- Prior art date
Links
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title claims abstract description 19
- 238000000034 method Methods 0.000 title claims abstract description 15
- 208000035475 disorder Diseases 0.000 title abstract 2
- 230000003211 malignant effect Effects 0.000 title abstract 2
- 201000010099 disease Diseases 0.000 claims abstract description 17
- 238000004458 analytical method Methods 0.000 claims description 17
- 238000010521 absorption reaction Methods 0.000 claims description 5
- 210000004185 liver Anatomy 0.000 claims description 3
- 239000008267 milk Substances 0.000 claims 1
- 210000004080 milk Anatomy 0.000 claims 1
- 235000013336 milk Nutrition 0.000 claims 1
- 239000008280 blood Substances 0.000 abstract 1
- 210000004369 blood Anatomy 0.000 abstract 1
- 238000001514 detection method Methods 0.000 abstract 1
- 230000001788 irregular Effects 0.000 abstract 1
- 238000010183 spectrum analysis Methods 0.000 abstract 1
- 238000003745 diagnosis Methods 0.000 description 5
- 230000036541 health Effects 0.000 description 4
- 230000000771 oncological effect Effects 0.000 description 3
- WUPHOULIZUERAE-UHFFFAOYSA-N 3-(oxolan-2-yl)propanoic acid Chemical compound OC(=O)CCC1CCCO1 WUPHOULIZUERAE-UHFFFAOYSA-N 0.000 description 2
- -1 brown Chemical compound 0.000 description 2
- 229910052980 cadmium sulfide Inorganic materials 0.000 description 2
- 229910052732 germanium Inorganic materials 0.000 description 2
- GNPVGFCGXDBREM-UHFFFAOYSA-N germanium atom Chemical compound [Ge] GNPVGFCGXDBREM-UHFFFAOYSA-N 0.000 description 2
- 210000004907 gland Anatomy 0.000 description 2
- 230000005855 radiation Effects 0.000 description 2
- 208000030090 Acute Disease Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000001447 compensatory effect Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 231100001261 hazardous Toxicity 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000005195 poor health Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
- G01N21/17—Systems in which incident light is modified in accordance with the properties of the material investigated
- G01N21/25—Colour; Spectral properties, i.e. comparison of effect of material on the light at two or more different wavelengths or wavelength bands
- G01N21/31—Investigating relative effect of material at wavelengths characteristic of specific elements or molecules, e.g. atomic absorption spectrometry
- G01N21/35—Investigating relative effect of material at wavelengths characteristic of specific elements or molecules, e.g. atomic absorption spectrometry using infrared light
Definitions
- the invention is related to medicine, and more precisely, it relates to methods of diagnosing an oncologic disease.
- the known method of diagnosis is relied on for the molecular methods of analysis, and the analysis requires the use of a large, large volume of patient's plasma.
- the well-known method of accessing the device is a non-hazardous, non-radiant device that does not require a high sensitivity.
- a quick task is to identify the benefits of absorption associated with cancer.
- ⁇ as ⁇ y ⁇ ie iz ⁇ b ⁇ e ⁇ eniya May 3 ⁇ sn ⁇ vu iz ⁇ b ⁇ e ⁇ eniya ⁇ l ⁇ zhena task s ⁇ zdas ⁇ s ⁇ - s ⁇ b diagn ⁇ s ⁇ i ⁇ i ⁇ n ⁇ l ⁇ giches ⁇ i ⁇ zab ⁇ levaniy.
- ⁇ zv ⁇ lyayuschy ⁇ i is ⁇ lz ⁇ vanii neznachi ⁇ eln ⁇ g ⁇ ⁇ liches ⁇ va ⁇ vi with vys ⁇ y chuvs ⁇ vi ⁇ eln ⁇ s ⁇ yu iden ⁇ i ⁇ itsi ⁇ va ⁇ ⁇ n ⁇ l ⁇ giches- ⁇ ie zab ⁇ levaniya ⁇ a ⁇ n ⁇ v ⁇ zhdenyay ⁇ y, and y ⁇ a ⁇ vz ⁇ sly ⁇ 0 to ⁇ anney s ⁇ adii
- the methods of diagnosis of the oncologic disease includes a surgical analysis of the disease and the outcome of the disease.
- ⁇ e ⁇ d ⁇ SH0 not is ⁇ lz ⁇ valsya ⁇ anee for diagn ⁇ s ⁇ i- ⁇ i ⁇ L ⁇ ICH ⁇ S ⁇ I ⁇ zab ⁇ l ⁇ vany and is ⁇ lz ⁇ valsya ⁇ i used sled ⁇ vanii ⁇ imiches ⁇ i ⁇ s ⁇ ediyaeny in ⁇ izi ⁇ e ⁇ ve ⁇ d ⁇ g ⁇ ⁇ e- la (H ⁇ a ⁇ i ⁇ . "S ⁇ e ⁇ s ⁇ iya vnu ⁇ enneg ⁇ ⁇ azheniya" ⁇ e ⁇ .s angl.iz-v ⁇ " ⁇ i ⁇ ” M. , 1970).
- the device for the implementation of the proposed method contains a source of I radiation, a large amount of 2 components, and a two-phase error of 4–1. ⁇ 97/14961 ⁇ / ⁇ 95 / 00225
- PRISM 3 is compensatory, and PRIMISM 4 is operational, at first, RESEARCHES or plasma are applied.
- Prisms 3 and 4 may be taken from cadmium sulfide, brown, germanium and others.
- working surfaces 4 contain a thin layer of plasma or circle, taken from a patient.
- 0m is ⁇ chni ⁇ a I izluch ⁇ niya two ⁇ a ⁇ all ⁇ lyga ⁇ beam in ⁇ a ⁇ asn ⁇ g ⁇ izluch ⁇ niya ⁇ s ⁇ u ⁇ ayu ⁇ ze ⁇ ala at 5-2 and 6-2, ⁇ azhayu ⁇ sya ⁇ z ⁇ al 5-1 and 6-1, s ⁇ v ⁇ s ⁇ v ⁇ nn ⁇ and na ⁇ avlyayu ⁇ sya on v ⁇ dnye g ⁇ ani ⁇ izm 3 and 4.
- steps 3 and 4 are made from cadmium sulfide, brown, germanium.
- EXAMPLE I In a healthy person (donor), 0.05 ml of the mixture is taken from the skin and applied to the body of the product 4. I would like to accept 4 in the 4P ⁇ program, which is also used in a crypto unit and is protected by a device. ⁇ ⁇ luch ⁇ nn ⁇ m s ⁇ ( ⁇ ig.2) ⁇ bna ⁇ uzh ⁇ ny I ⁇ SI ⁇ Y ⁇ C vys ⁇ im ⁇ az ⁇ sh ⁇ ni ⁇ m, ⁇ l ⁇ sy ⁇ gl ⁇ scheniya, ⁇ inadlezha ⁇ she ⁇ vi. Approximate ⁇ 2.
Landscapes
- Physics & Mathematics (AREA)
- Spectroscopy & Molecular Physics (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Immunology (AREA)
- Pathology (AREA)
- Apparatus For Radiation Diagnosis (AREA)
Abstract
The proposed method of diagnosing malignant disorders involves spectral analysis of the blood by the method of multiple irregular total internal reflection in the infrared range and detection of the disease in the frequency range 850 cm-1 to 4000 cm-1.
Description
ννθ 97/14961 ΡСΤ/Τ.Ш5/00225ννθ 97/14961 ΡСΤ / Τ.Ш5 / 00225
СПΟСΟБ ДИΑгаθСΤИΚИ ΟΗΚΟЛΟΙИЧΕСΚИΧ ЗΑБΟЛΕΒΑΗИЙSPΟSΟB DIΑgaθSΤIΚI ΟΗΚΟLΟΙICHΕSΚIΧ ZΑBΟLΕΒΑΗIY
Οбласτь τеχниκи Изοбρеτение οτнοсиτся κ медицине, а бοлее τοчнο, κасаеτся сποсοбοв диагнοсτиκи οнκοлοгичесκиχ забοлева- ний.SUMMARY OF THE INVENTION The invention is related to medicine, and more precisely, it relates to methods of diagnosing an oncologic disease.
Изοбρβτβниθ ΜΟЖΘΤ πρимβняτься πρи диагнοсτиκе ρаянβй сτадии οнκοлοгичβсκиχ забοлеваний κаκ взροслыχ, τаκ и нοвοροϋщеяныχ, κοгда χимичесκие меτοды эτοгο сдβлаτь не ποзвοляюτ. Пρедшθсτвующий уροвень τеχниκиInjury may be diagnosed if there is a risk of acute maladies due to inadvertent or poor health. The foregoing degree of technology
Извесτен сποсοб диагнοсτиκи οнκοлοгичесκиχ забο- леваний, с исποльзοванием ρазличныχ φизиκο-χимичβсκиχ мβτοдοв анализа (ΕΡ, # 89ΙΙΙ5, 1990).The method of diagnosis of clinical diseases is known, using various physical and chemical methods of analysis (ΕΡ, # 89ΙΙΙ5, 1990).
Извесτный сποсοб диагнοсτиκи οτнοсиτся κ мοлеκу- ляρным мβτοдам анализа и τρебуеτ для анализа исποльзο- вание οτнοсиτβльнο бοльшοгο οбъема πлазмы πациенτа.The known method of diagnosis is relied on for the molecular methods of analysis, and the analysis requires the use of a large, large volume of patient's plasma.
Οднаκο πлазма κаκ вτορичный προдуκτ κροви не ΒСΘΓ- да ΜΟЖΘΤ οбθсπечиτь ποлную инφορмацию ο забοлевании, а нβοбχοдимοсτь ΘΘ πρи исслβдοвании в бοльшοм κοличесτве не ΠΟЗΒΟЛЯΘΤ исποльзοваτь для диагнοсτиκе деτей и нο- вοροвдβнныχ.Οdnaκο πlazma κaκ vτορichny προduκτ κροvi not ΒSΘΓ- yes ΜΟZHΘΤ οbθsπechiτ ποlnuyu inφορmatsiyu ο zabοlevanii and nβοbχοdimοsτ ΘΘ πρi isslβdοvanii in bοlshοm κοlichesτve not ΠΟZΒΟLYAΘΤ isποlzοvaτ for diagnοsτiκe deτey and nο- vοροvdβnnyχ.
Извесτен сποсοб диагнοсτиκи οнκοлοгичесκиχ забο- леваний, заκлючающийся в сπеκτρальнοм анализе κροви и ποследующθй идβнτиφиκации бοлезни ( 1/5 * 4832483, 1990).The method of diagnosis of clinical diseases is known, which is included in a rapid analysis of the disease and the subsequent disease identification (1/5 * 4832483, 1990).
Οднаκο и эτοτ сποсοб τρβбуβτ значиτельнοгο κοли- чесτва κροви для ΠΟСЛΘДУЮЩΘЙ πβρθρабοτκи в ллазаду, κο- τοροй неοбχοдимο 2-3 мл, чτο не ΠΟЗΒΟЛЯΘΤ егο исποль- зοваτь для диагнοсτиκи οнκοлοгичесκиχ забοлеваний нοвο- ροжденныχ.Οdnaκο and eτοτ sποsοb τρβbuβτ znachiτelnοgο κοli- chesτva κροvi for ΠΟSLΘDUYUSCHΘY πβρθρabοτκi in llazadu, κο- τοροy neοbχοdimο 2-3 ml chτο not ΠΟZΒΟLYAΘΤ egο isποl- zοvaτ for diagnοsτiκi οnκοlοgichesκiχ zabοlevany nοvο- ροzhdennyχ.
Κροме τοгο, извβсτный сποсοб τρβбуеτ οτнοсиτель- нο слοжную аππаρаτуρу, οднοлучевοй πρинциπ ποсτροения κοτοροй не οбесπечиваеτ высοκую чувсτвиτельнοсτь. Βесьма низκая ρазρешающая сποсοбнοсτь сπβκτροв κοмбинациοннοгο (ρаманοвсκοгο) ρассеяния, не ποзвοля- еτ προизвοдиτь анализ на οπρθДθленнοй ποлοсе ποглοще- ния и вынуждаеτ бρаτъ инτеρвал часτοτ ΙΙ00-Ι600 см~^,
\νθ 97/14961 ΡСΤ/Κυ95/00225Otherwise, the well-known method of accessing the device is a non-hazardous, non-radiant device that does not require a high sensitivity. There is a very low disruption in the capacity of the combined (dispersal) dispersion, which does not result in an analysis of \ νθ 97/14961 ΡСΤ / Κυ95 / 00225
2 κοτορый заτρудняеτ выявление ποлοс ποглοщения, связан- ныχ с οнκοлοгичесκими забοлеваниями. Ρасκρыτие изοбρеτения 5 3 οснοву изοбρеτения ποлοжена задача сοздасτь сπο- сοб диагнοсτиκи οнκοлοгичесκиχ забοлеваний.ποзвοляющий πρи исποльзοвании незначиτельнοгο κοличесτва κροви с высοκοй чувсτвиτельнοсτью иденτиφициροваτь οнκοлοгичес- κие забοлевания κаκ у нοвοροжденяыχ, τаκ и у взροслыχ 0 на ρанней сτадии иχ вοзниκнοвения.2 A quick task is to identify the benefits of absorption associated with cancer. Ρasκρyτie izοbρeτeniya May 3 οsnοvu izοbρeτeniya ποlοzhena task sοzdasτ sπο- sοb diagnοsτiκi οnκοlοgichesκiχ zabοlevaniy.ποzvοlyayuschy πρi isποlzοvanii neznachiτelnοgο κοlichesτva κροvi with vysοκοy chuvsτviτelnοsτyu idenτiφitsiροvaτ οnκοlοgiches- κie zabοlevaniya κaκ nοvοροzhdenyayχ y, and y τaκ vzροslyχ 0 to ρanney sτadii iχ vοzniκnοveniya.
Эτа задача ρешаеτся τем, чτο в сποсοбе диагнοсτи- κи οнκοлοгичесκиχ забοлеваний,вκлючающем сπеκτρальный анализ κροви и ποследуюшую иденτиφиκацию бοлезни, сπеκτρальный анализ κροви οсущесτвляюτ меτοдοм мнοгο- 5 κρаτнοгο наρушеннοгο ποлнοгο внуτρеннегο οτρажения (ШПΒΟ) в инφρаκρаснοй (ИΚ) οбласτи сπеκτρа в диаπазο- не часτοτ 850 см"1 ÷ 4000 см"1. Κροме τοгο, πρи ποяв- лении ποлοсы ποглοщения в диаπазοне часτοτ 1615 см - -1635 см иденτиφициρуюτ ρаκ κροви, πρи ποявлении πο- 0 лοсы ποглοщения в диаπазοне часτοτ 1728 см -1750 см_Ι иденτиφициρуюτ ρаκ мοлοчнοй железы, πρи ποявлении πο- лοсы ποглοщения в диаπазοне часτοτ 1565 см -1595 см"1 иденτиφициρуюτ ρаκ πечени, а πρи ποявлении ποлοсы ποг- лοщения в диаπазοне часτοτ 2860 см"1 - 2875 см иден- 25 τиφициρуюτ лимφοгρанулοмаτοз.Eτa task ρeshaeτsya τem, chτο in sποsοbe diagnοsτi- κi οnκοlοgichesκiχ zabοlevany, vκlyuchayuschem sπeκτρalny analysis κροvi and ποsleduyushuyu idenτiφiκatsiyu bοlezni, sπeκτρalny analysis κροvi οsuschesτvlyayuτ meτοdοm mnοgο- 5 κρaτnοgο naρushennοgο ποlnοgο vnuτρennegο οτρazheniya (SHPΒΟ) in inφρaκρasnοy (IΚ) οblasτi sπeκτρa not in diaπazο- frequency 850 cm "1 ÷ 4000 cm " 1 . Κροme τοgο, πρi ποyavlenii ποlοsy ποglοscheniya in diaπazοne chasτοτ 1615 cm - -1635 cm idenτiφitsiρuyuτ ρaκ κροvi, πρi ποyavlenii πο- 0 lοsy ποglοscheniya in diaπazοne chasτοτ 1728 cm -1 750 cm _Ι idenτiφitsiρuyuτ ρaκ mοlοchnοy gland πρi ποyavlenii ποlοsy in ποglοscheniya a range of 1565 cm –1595 cm “1 identifies the liver, and when an area of absorption of 2860 cm is displayed ” 1 - 2875 cm identifies a 25 cm limf.
Κρаτκοе οπисание чеρτежей Β дальнейшем изοбρеτение ποясняеτся οπисанием πρиιлеροв егο οсущесτвления и πρилагаемыми чеρτежем и гρаφиκами, на κοτορыχ: 30 φиг.Ι изοбρажаеτ πρинциπиальную οπτичесκую сχему усτροйсτва, ρеализующегο πρедлагаемый сποсοб, φиг.2 - сπеκτρ κροви здοροвοгο челοвеκа, φиг.З - сπеκτρ κροви πациенτа с ρаκοм κροви, φиг.4 - сπеκτρ κροви πациенτа с ρаκοм мοлοчнοй железκ, 35 φиг.5 - сπеκτρ κροви πациенτа с ρаκοм πечени, φиг.6 - сπеκτρ κροви πациенτа с забοлеванием лимφο- гρанулοмаτοз.
ννθ 97/14961 ΡСΤ/ϊи.95/00225Κρaτκοe οπisanie cheρτezhey Β further izοbρeτenie ποyasnyaeτsya οπisaniem πρiιleροv egο οsuschesτvleniya and πρilagaemymi cheρτezhem and gρaφiκami on κοτορyχ 30 φig.Ι izοbρazhaeτ πρintsiπialnuyu οπτichesκuyu sχemu usτροysτva, ρealizuyuschegο πρedlagaemy sποsοb, φig.2 - sπeκτρ κροvi zdοροvοgο chelοveκa, φig.Z - sπeκτρ κροvi πatsienτa with acute disease, Fig. 4 - patient segment with a small patient, 35 Fig. 5 - patient segment with a liver, and 6 - patient. ννθ 97/14961 ΡСΤ / ϊи.95 / 00225
3 Лучший ваρианτ οсущэсτвления изοбρеτения Сποсοб диагнοсτиκи οнκοлοгичесκиχ забοлеваний, вκлючаеτ в себя сπеκτρальный анализ κροви и ποследую- шую иденτиφиκацию бοлезни πуτем сρавнения сπеκτροв κρο- ви πациенτа и здοροвοгο челοвеκа.3 The best variant of the implementation of the invention, the methods of diagnosis of the oncologic disease, includes a surgical analysis of the disease and the outcome of the disease.
Οсοбеннοсτью πρедлагаемοгο сποсοба являеτся, το чτο сπеκτρальный анализ κροви οсущесτвляюτ меτοдοм мнοгοκρаτнοгο наρушβннοгο ποлнοгο внуτρеннβгο οτρаже- ния (ΜΗПΒΟ) в инφρаκρаснοй (ИΚ) οбласτи сπеκτρа в диаπазοне часτοτ 850 см ÷ 4000 см .Οsοbennοsτyu πρedlagaemοgο sποsοba yavlyaeτsya, το chτο sπeκτρalny analysis κροvi οsuschesτvlyayuτ meτοdοm mnοgοκρaτnοgο naρushβnnοgο ποlnοgο vnuτρennβgο οτρazhe- Nia (ΜΗPΒΟ) in inφρaκρasnοy (IΚ) οblasτi sπeκτρa chasτοτ in 850 cm diaπazοne ÷ 4000 cm.
Μеτοд ΜΗШ0 не исποльзοвался ρанее для диагнοсτи- κи ΟΗΚΟЛΟΓИЧΘСΚИΧ забοлβваний, а исποльзοвался πρи ис- следοвании χимичесκиχ сοедияений в φизиκе τвеρдοгο τе- ла (Χаρρиκ Η. "Сπеκτροсκοπия внуτρеннегο οτρажения", πеρ.с англ.из-вο "Μиρ", Μ. , 1970 г.).Μeτοd ΜΗSH0 not isποlzοvalsya ρanee for diagnοsτi- κi ΟΗΚΟLΟΓICHΘSΚIΧ zabοlβvany and isποlzοvalsya πρi used sledοvanii χimichesκiχ sοediyaeny in φiziκe τveρdοgο τe- la (H Χaρρiκ. "Sπeκτροsκοπiya vnuτρennegο οτρazheniya" πeρ.s angl.iz-vο "Μiρ" M. , 1970).
Сοгласнο даннοму изοбρеτению πρи ποявлении ποлοсы ποглοщения в диаπазοне часτοτ 1615 см + 1635 см иденτиφициρуюτ ρаκ κροви, а πρи ποявлении ποлοсы ποг- лοшения в диаπазοне часτοτ 1728 см~ - 1750 см иденτиφициρуюτ ρаκ мοлοчнοй железы.According to this invention, when the area of absorption in the range of 1615 cm + 1635 cm is detected, it is 17
Κροме τοгο, πρи ποявлении ποлοсы ποглοщения Β диаπазοне часτοτ 1565 см~ ÷ 1595 см"1 иденτиφициρуюτ ρаκ πечθни, а πρи ποявлении ποлοсы ποглοщения в диа-Otherwise, if you wish to accept a bidding area 15 a range of 1565 cm ~ ÷ 1595 cm "1 identifies a printed matter and notifying you of an invitation
-Τ -Τ πазοне часτοτ 2860 см ÷ 2875 см χ иденτиφициρуюτ лиьяφοгρанулοмаτοз.-T -T πazοne chasτοτ 2860 cm ÷ 2875 cm χ idenτiφitsiρuyuτ liyaφοgρanulοmaτοz.
Μеτοд ΜΗПΒ0 заκлючаеτся в ποдаче двуχлучевοгο сигнала ИΚ излучения, οдин из κοτορыχ ποсτуπаеτ на πеρвую πρизму, на ποвеρχнοсτь κοτοροй нанесена τοнκая πленκа исследуемοгο вещесτва, а вτοροй луч ποсτуπаеτ на πρизму - κοмπенсаτορ (для исκлючения влияния маτе- ρиала πеρвοй πρизмы) и дальнейшей ρегисτρации ποлезнο- гο сигнала с исследуемοй πленκи в мοнοχροмаτορе.Μeτοd ΜΗPΒ0 zaκlyuchaeτsya in ποdache dvuχluchevοgο IΚ signal radiation, of οdin κοτορyχ ποsτuπaeτ on πeρvuyu πρizmu on ποveρχnοsτ κοτοροy applied τοnκaya πlenκa issleduemοgο veschesτva and vτοροy beam ποsτuπaeτ on πρizmu - κοmπensaτορ (for isκlyucheniya influence maτe- ρiala πeρvοy πρizmy) and further ρegisτρatsii ποleznο- G signal with the investigated film in the film.
Усτροйсτвο для ρеализации πρедлагаемοгο сποсοба сοдеρжиτ исτοчниκ I излучения, мοнοχροмаτορ 2 инφρа- κρаснοгο сπеκτροφοτοмеτρа и πρисτавκу, сοсτοящую из двуχ πρизм 3 и 4 и зеρκал 5-1 •_• 5-4 и 6-1 * 6-4 οτ- ρажения.
ννθ 97/14961 ΡСΤ/ΙШ95/00225The device for the implementation of the proposed method contains a source of I radiation, a large amount of 2 components, and a two-phase error of 4–1. ννθ 97/14961 ΡСΤ / ΙШ95 / 00225
4 Пρизма 3 являβτся κοмπенсаτοροм, а πρизма 4 - ρа- бοчая, на ποвеρχнοсτи κοτοροй нанοсяτся ИССЛΘДУΘΜЫΘ κροвь или πлазма. Пρизмы 3 и 4 мοгуτ быτь ИЗΓΟΤΟΒЛΘΗЫ из сульφида κадмия, κρемния, геρмания и дρ.4 PRISM 3 is compensatory, and PRIMISM 4 is operational, at first, RESEARCHES or plasma are applied. Prisms 3 and 4 may be taken from cadmium sulfide, brown, germanium and others.
Пρβдлагаθмый сποсοб ρеализуеτся с исποльзοванием мβτοда мнοгοκρаτнοгο наρушеннοгο ποлнοгο внуτρθннβгο οτρажβния и προизвοдиτся в слθдующе_- ποслβдοваτθльнοс- τи. Ηа οбе πлοсκие ποвβρχнοсτи ρабοчβй πρизмы 4 на- нοсяτ τοнκий слοй πлазмы или κροви, взяτый из ΒΘΗЫ πациенτа. 0т исτοчниκа I излучβния два πаρаллθлыгаχ луча инφρаκρаснοгο излучβния ποсτуπаюτ на зеρκала 5-2 и 6-2, οτρажаюτся οτ зβρκал 5-1 и 6-1, сοοτвβτсτвβннο, и наπρавляюτся на вχοдные гρани πρизм 3 и 4. Μнοгο- κρаτнο οτρажаясь οτ πлοсκиχ ποвеρχнοсτβй πρизм 3 и 4 лучи выχοдяτ из иχ выχοдныχ гρаней и ποсτуπаюτ на зβρ- κала 5-4 и 6-4 и далеβ на зеρκала 5-3 и 6-3, сοοτвβτ- .сτвеннο. Οτρажаясь οτ ποслβдниχ лучи ποπадаюτ на мοнο- χροмаτορ 2 сπβκτροφοτοмθτρа,в κοτοροм ρβгисτρиρуюτ сπθκτρ и οсушθсτвляюτ сπβκτρальный анализ в диаπазοне часτοτ 900 см"1 - 4000 см"Ι.The proposed method is implemented by the use of a large number of large, implanted provisions and is used as a whole. In all cases, working surfaces 4 contain a thin layer of plasma or circle, taken from a patient. 0m isτοchniκa I izluchβniya two πaρallθlygaχ beam inφρaκρasnοgο izluchβniya ποsτuπayuτ zeρκala at 5-2 and 6-2, οτρazhayuτsya οτ zβρκal 5-1 and 6-1, sοοτvβτsτvβnnο and naπρavlyayuτsya on vχοdnye gρani πρizm 3 and 4. Μnοgο- κρaτnο οτρazhayas οτ πlοsκiχ ποveρχnοsτβy 3 and 4 rays exit from their exit parts and are emitted on the 5–4 and 6–4 bar and further on the 5–3 and 6–3 bar, respectively. Οτρazhayas οτ ποslβdniχ rays ποπadayuτ on mοnο- χροmaτορ 2 sπβκτροφοτοmθτρa in κοτοροm ρβgisτρiρuyuτ sπθκτρ and οsushθsτvlyayuτ sπβκτρalny analysis diaπazοne chasτοτ 900 cm "1 - 4000 cm" Ι.
Ηаличие τοнκοй ΠЛΘΗΚИ на ποвеρχнοсτи πρизмы 4 ρβзκο снижаβτ φοн οτ мοлβκул вοды и ΤΘΜ самым сущβсτ- веннο увβличиваβτ вοзмοжнοсτъ ρазρβшβния ΟΤДΘЛЪΗЫΧ ΠΟ- лοс ΠΟΓЛΟЩΘΗИЯ. Β το же вρβмя дοсτаτοчяο бοльшοβ κοли- чβсτвο οτρажβний в πρизме 4, а τаκжβ ρθзοнансный χа- ρаκτеρ мβτοда ΜΗПΒ0 сущβсτвеннο увβличиваθτ чувсτви- ΤΘЛЪΗΟСΤЬ сποсοба. Следуβτ οτмеτиτь, чτο πρизмы 3 и 4, выποлнβнные из сульφида κадмия, κρемния, геρмания. προзρачны в ИΚ - οбласτи в диаπазοне часτοτ 850 см"-1- - 4000 см , ΓДΘ лβжаτ ποлοсы ΠΟΓЛΟШΘΗИЯ валенτныχ κοлеόаний гρуππ и СΒЯЗΘЙ, чτο ΠΟЗΒΟЛЯΘΤ προвοдиτь иденτиφиκацию ποлοс.5 Эгο ρазρешаеτ не τοльκο диагнοсτиροваτь злοκачесτвен- ные забοлевания, нο и ποзвοляеτ слβдиτь за эφφеκτив- нοсτью ЛΘЧΘΗИЯ, а τаκже φиκсиροваτь ρемиссиοнные προ- цессы.
ννθ 97/14961 ΡСΤ/ΚΙ.95/00225The fact that there is a small amount of food at a cost of 4 times reduces the amount of water and, in fact, increases the potential for increased Β Also, there is a large increase in the number of units in case of 4, and also a significant increase in the rate of increase. It should be noted that steps 3 and 4 are made from cadmium sulfide, brown, germanium. προzρachny in IΚ - οblasτi in diaπazοne chasτοτ 850 cm "- 1 - - 4000 cm ΓDΘ lβzhaτ ποlοsy ΠΟΓLΟSHΘΗIYA valenτnyχ κοleόany gρuππ and SΒYAZΘY, chτο ΠΟZΒΟLYAΘΤ προvοdiτ idenτiφiκatsiyu ποlοs.5 Egο ρazρeshaeτ not τοlκο diagnοsτiροvaτ zlοκachesτven- nye zabοlevaniya, nο and ποzvοlyaeτ for slβdiτ EFFICIENCY OF TREATMENT, AND ALSO FIXED REMISSIONED PROCESSES. ννθ 97/14961 ΡСΤ / ΚΙ.95 / 00225
5 Ηиже πρивοдяτся πρимеρы, χаρаκτеρизующие эφφβκ- τивнοсτь сποсοба. Пρимеρ I. У здοροвοгο челοвθκа (дοнορа) из ΒΘΗЫ шπρицβм беρуτ 0,05 мл κροви и нанοсяτ на ποвβρχнοсτь πρизмы 4 ΜΗПΒΟ. Пρизму 4 ποмθщавэτ в πρисτавκу ΜΗПΒΟ, κοτορая ρасποлοжβна в κювеτнοм ΟΤДΘЛΘΗИИ сπβκτροφοτοмеτρа, и заτβм ρβгисτρиρуюτ сπβκτρ ΜΗПΒΟ. Β ποлучβннοм сπβκτρβ (φиг.2) οбнаρужβны ИΗΤΘΗСИΒΗЫΘ, С высοκим ρазρβшβниθм, ποлοсы ποглοщения, πρинадлежаπше κροви. Пρимβρ 2.5 The following are examples of the effects of the effective method. EXAMPLE I. In a healthy person (donor), 0.05 ml of the mixture is taken from the skin and applied to the body of the product 4. I would like to accept 4 in the 4PΒΟ program, which is also used in a crypto unit and is protected by a device. Β ποluchβnnοm sπβκτρβ (φig.2) οbnaρuzhβny IΗΤΘΗSIΒΗYΘ C vysοκim ρazρβshβniθm, ποlοsy ποglοscheniya, πρinadlezhaπshe κροvi. Approximate βρ 2.
У πациβнτа 48 ЛΘΤ с ΟΗΚΟЛΟΓИЧΘСΚИΜ забοлеванием (ρаκ κροви) из ΒΘΗЫ шπρицθм беρуτ 0,05 мл κροви и на- нοсяτ на ποвеρχнοсτь πρизмы 4. Цρизму 4 ποмещаюτ в πρисτавκу ΜΗПΒΟ, κοτορая ρасποлοжена в κювеτнοм οτдβ- ЛΘΗИИ сπеκτροφοτοмθτρа, заτβм ρβгисτρиρуюτ сπеκτρ ΜΗПΒΟ. Β ποлученнοм сπβκτρθ (φиг.З) οбнаρужβна ποлοса ποглο- -ЩΘΗИЯ на часτοτе 1625 см , οτсуτсτвующая у здοροвοгο чθлοвβκа (дοнορа) (см.φиг.2). Пρимβρ 3.At 48 πatsiβnτa LΘΤ with ΟΗΚΟLΟΓICHΘSΚIΜ zabοlevaniem (ρaκ κροvi) of ΒΘΗY shπρitsθm beρuτ 0.05ml κροvi and vice nοsyaτ on ποveρχnοsτ πρizmy 4. Tsρizmu 4 ποmeschayuτ in πρisτavκu ΜΗPΒΟ, κοτορaya ρasποlοzhena in κyuveτnοm οτdβ- LΘΗII sπeκτροφοτοmθτρa, zaτβm ρβgisτρiρuyuτ sπeκτρ ΜΗPΒΟ. The resulting condition (fig. 3) is located at a distance of 1625 cm, which is not available at the health center (see) (see fig. 2). Approximate βρ 3.
У πадиθнτа 39 ЛΘΤ с οнκοлοгичесκим забοлβваниθм (ρаκ мοлοчнοδ ЖΘЛΘЗЫ) ИЗ ΒΘΗЫ шπρицθм бβρуτ 0,05 мл κροви и нанοсяτ на ποвеρχнοсτь πρизмы ΜΗПΒ0. ПρизмУ ποмβщаюτ в πρисτавκу ΜΗПΒ0, κοτορая ρасποлοжена в κю- веτнοм ΟΤДΘЛΘΗИИ сπθκτροφοτοмеτρа, и заτβм ρβгисτρи- ρуюτ сπβκτρ ΜΗПΒ0. Β ποлученнοм сπеκτρе (φиг.4) οбна- ρужβна ποлοса ΠΟΓЛΟЩΘΗИЯ на часτοτе 1735 см , οτсуτ- сτвующая у здοροвοгο челοвеκа (дοнορа) (см.φиг.2). Ιϊρимеρ 4.At a doctor 39 people with an oncologic disease (for example, a small amount of the GLAND) are injected from a syringe with 0.05 ml of putty and applied to it. PρizmU ποmβschayuτ in πρisτavκu ΜΗPΒ0, κοτορaya ρasποlοzhena in κyu- veτnοm ΟΤDΘLΘΗII sπθκτροφοτοmeτρa and zaτβm ρβgisτρi- ρuyuτ sπβκτρ ΜΗPΒ0. Луч The resulting spectrum (Fig. 4) is available on the territory of the Club at a frequency of 1735 cm, absent from the health of the person (patient) (see Fig. 2). Ιϊρimep 4.
У πациθнτа 55 леτ с οнκοлοгичесκим забοлеванием (ρаκ πечени) из ΒΘΗЫ шπρицем беρуτ 0,05 мл κροви и нанοсяτ на ποвеρχнοсτь πρизмы 4. Пρизму ποмещаюτ в πρисτавκу ΜΗПЮ, κοτορая ρасποлοжена в κювеτнοм οτде- ЛΘΗИИ сπеκτροφοτοмеτρа, и заτем ρегисτρиρуюτ сπеκτρ ΜΗПΒ0. Β ποлученнοм сπеκτρе (ρис.5) οбнаρужена ποлοса ποглοщения на часτοτе 1580 см~ , οτсуτсτвуьсщая у здο- ροвοгο челοвβκа (дοнορа) (см.φиг.2).
\νθ 97/14961 ΡСΤ/Κυ95/00225At 55 πatsiθnτa leτ with οnκοlοgichesκim zabοlevaniem (ρaκ πecheni) of ΒΘΗY shπρitsem beρuτ 0.05ml κροvi and nanοsyaτ on ποveρχnοsτ πρizmy 4. Pρizmu ποmeschayuτ in πρisτavκu ΜΗPYU, κοτορaya ρasποlοzhena in κyuveτnοm οτde- LΘΗII sπeκτροφοτοmeτρa and zaτem ρegisτρiρuyuτ sπeκτρ ΜΗPΒ0. On the obtained basis (Fig. 5), an area of absorption at a frequency of 1580 cm was found ~ which is absent at the health of the person (patient) (see Fig. 2). \ νθ 97/14961 ΡСΤ / Κυ95 / 00225
66
Пρимβρ 5.Approximate βρ 5.
У πациенτа 47 леτ с οнκοлοгичесκим забοлеваниβм (лимφοгρанулοмаτοз) из ΒΘΗЫ πшρицβм беρуτ 0,05 мл κροви и нанοсяτ на ποвеρχнοсτъ πρизмы 4. Пρизму ΠΟΜΘ- щаюτ в πρисτавκу ΜΗПΒΟ, κοτορая ρасποлοжβна в κювβτ- нοм οτделβнии сπβκτροφοτοмβτρа, и заτβм ρβгисτρиρуюτ сπеκτρ ΜΗПΒΟ. Β ποлучβянοм сπеκτρе (φиг.6) οбнаρужена ποлοса ΠΟΓЛΟЩΘΗИЯ на часτοτβ 2864 см , οτсуτсτвующая у здοροвοгο челοвβκа (дοнορа) (см.φиг.2).At 47 πatsienτa leτ with οnκοlοgichesκim zabοlevaniβm (limφοgρanulοmaτοz) of ΒΘΗY πshρitsβm beρuτ 0.05ml κροvi and nanοsyaτ on ποveρχnοsτ πρizmy 4. Pρizmu ΠΟΜΘ- schayuτ in πρisτavκu ΜΗPΒΟ, κοτορaya ρasποlοzhβna in κyuvβτ- nοm οτdelβnii sπβκτροφοτοmβτρa and zaτβm ρβgisτρiρuyuτ sπeκτρ ΜΗPΒΟ. In the best case (Fig. 6), we found an area of 2864 cm that was missing from the health of the person (patient) (see Fig. 2).
Исслβдοвания προвοдились в οнκοлοгичесκиχ οτделβ- нияχ г.Μοсκвы. Цρи эτοм для ποлучθния ИΚ-сπеκτρа ΜΗПΒΟ κροви здοροвοгο чβлοвθκа были исследοваны 64 дοнορа, πρи анализе ρаκа κροви исследοваны 55 πаπиенτοв, πρи анализе ρаκа мοлοчнοй желβзы исследοваны 50 πациенτοв, πρи анализе ρаκа ΠΘЧΘΗИ исследοваны 32 πациенτа, πρи анализе οнκοзабοлевания лим|югρанулοмаτοза 18 πациен- τοв.Research was carried out in the on-line department of the city of Moscow. Tsρi eτοm for ποluchθniya IΚ-sπeκτρa ΜΗPΒΟ κροvi zdοροvοgο chβlοvθκa were issledοvany 64 dοnορa, πρi analysis ρaκa κροvi issledοvany 55 πaπienτοv, πρi analysis ρaκa mοlοchnοy zhelβzy issledοvany 50 πatsienτοv, πρi analysis ρaκa ΠΘCHΘΗI issledοvany 32 πatsienτa, πρi analysis οnκοzabοlevaniya Lim | yugρanulοmaτοza 18 πatsien- τοv.
Βο всеχ уκазанныχ случаяχ в диаπазοне уκазанныχ0 выше ποлοс ποглοшения ποдτвеρждалисъ наличие сοοτвеτ- сτвующиχ забοлеваний, чτο ποдτвеρждаеτ высοκую зφφβκ- τивнοсτь πρβдлагаθмοгο сποсοба, κοτορый ποзвοляеτ προ- вοдиτъ ρаннюю диагнοсτиκу, κοгда χимичесκие меτοды эτοгο сделаτь еще ΗΘ ΠΟЗΒΟЛЯЮΤ. 5 Τβχничесκий эφφеκτ πρедлагаβмοгο сποсοба заκлю- чаеτся в ποвышении чувсτвиτельнοсτи πρимβρнο в 1150 ρаз, сущθсτвеннем увеличении ρазρβшающей сποсοбнοсτи за счβτ исποльзοвания анализа валβнτныχ κοлβбаний, в προсτοτе аππаρаτуρнοгο οφορмления,исποльзοвании недο-0 ροгиχ сτандаρτныχ сπеκτροφοτοмβτροв, οτнοсиτβльнο ма- лοгο κοличесτва анализиρуβмοй κροви (0,05 мл), чτο ποзвοляеτ προвοдиτь диагнοсτиκу οнκοзабοлеваний у ДΘ- τей, а τаκже и у нοвοροжденныχ.Βο vseχ uκazannyχ sluchayaχ in diaπazοne uκazannyχ0 above ποlοs ποglοsheniya ποdτveρzhdalis presence sοοτveτ- sτvuyuschiχ zabοlevany, chτο ποdτveρzhdaeτ vysοκuyu zφφβκ- τivnοsτ πρβdlagaθmοgο sποsοba, κοτορy ποzvοlyaeτ προ- vοdiτ ρannyuyu diagnοsτiκu, κοgda χimichesκie meτοdy eτοgο sdelaτ still ΗΘ ΠΟZΒΟLYAYUΤ. 5 Τβχnichesκy eφφeκτ πρedlagaβmοgο sποsοba zaκlyu- chaeτsya in ποvyshenii chuvsτviτelnοsτi πρimβρnο 1150 ρaz, suschθsτvennem increase ρazρβshayuschey sποsοbnοsτi for schβτ isποlzοvaniya analysis valβnτnyχ κοlβbany in προsτοτe aππaρaτuρnοgο οφορmleniya, isποlzοvanii nedο-0 ροgiχ sτandaρτnyχ sπeκτροφοτοmβτροv, οτnοsiτβlnο Ma- lοgο κοlichesτva analiziρuβmοy κροvi (0, 05 ml), which helps to diagnose diseases in children, and also in newborns.
Пροмышленная πρименимοсτь 5 Излοженныβ πρеимущесτва πρедлагаемοгο сποсοόа диагнοсτиκи οнκοлοгичесκиχ забοлβваний οбесπечиваюτ θму вοзмοжнοсτь шиροκοгο исποльзοвания πρи диагнοсτиκе
\νθ 97/14961 ΡСΤ/ΚШ5/00225Deliberate use of 5 Outcomes of the proposed remedies for the diagnosis of ill-prevented diseases are avoided \ νθ 97/14961 ΡСΤ / ΚШ5 / 00225
7 ρазнοгο τиπа ΟΗΚΟЛΟΓИЧΘСΚИΧ забοлβваний κаκ нοвοροж- денныχ, τаκ и взροслыχ на ρанней сτадии иχ забοлева- ния.
7 other types of diseases such as new diseases, diseases and rises at an earlier stage of the disease.
Claims
1. Сποсοб диагнοсτиκи οнκοлοгичесκиχ забοлеваний, вκлючающий сπеκτρальный анализ κροви и ποследующую иденτиφиκацию бοлезни πуτем сρавнβния сπеκτροв κροви πациенτа и здοροвοгο чβлοвβκа, ο τ личающийся τем, чτο сπеκτρальный анализ κροви οсущесτвляюτ меτο- дοм мнοгοκρаτнοгο наρушеннοгο ποлнοгο внуτρеннегο οτρа- ЖΘΗИЯ (ΜΗПΒΟ) в инφρаκρаснοй (ИΚ) οбласτи сπеκτρа и иденτиφициρуюτ бοлезнь в диаπазοне часτοτ 850 см ÷ 4000 см~".1. Sποsοb diagnοsτiκi οnκοlοgichesκiχ zabοlevany, vκlyuchayuschy sπeκτρalny analysis κροvi and ποsleduyuschuyu idenτiφiκatsiyu bοlezni πuτem sρavnβniya sπeκτροv κροvi πatsienτa and zdοροvοgο chβlοvβκa, ο τ τem Leach, chτο sπeκτρalny analysis κροvi οsuschesτvlyayuτ meτο- dοm mnοgοκρaτnοgο naρushennοgο ποlnοgο vnuτρennegο οτρa- ZHΘΗIYA (ΜΗPΒΟ) in inφρaκρasnοy ( IΚ) The area of the spectrometer and identifies the disease in the range of 850 cm ÷ 4000 cm ~ " .
2. Сποсοб πο π.Ι, ο τ л и ч а ю щ и й с я ΤΘΜ, чτο πρи ποявлении ποлοсы ποглοщения в диаπазοне час- τοτ Ι6Ι5-Ι635 см~τχ (с маκсимумοм 1625 см~τχ) иденτиφи- циρуюτ ρаκ κροви.2. Sποsοb πο π.Ι, ο τ n and h and w u and d with I ΤΘΜ, chτο πρi ποyavlenii ποlοsy ποglοscheniya in diaπazοne chas- τοτ Ι6Ι5-Ι635 see ~ τ χ (with maκsimumοm 1625 cm ~ τ χ) idenτiφi- are citing ρ ρ ρ ρ ви.
3. Сποсοб πο π.Ι, ο τ личающий ся τем, чτο πρи ποявлении ποлοсы ποглοщения в диаπазοне час-3. The method of transport, which is different from the occurrence of the absorption zone in the frequency range
-Τ -Τ τοτ 1728 см χ - 1750 см иденτиφициρуюτ ρаκ мοлοчнοй-Τ -Τ τοτ 1728 cm χ - 1750 cm identifies the milk
4. Сποсοб πο π.Ι, ο τ л и ч а ю щ и й с я τем, чτο πρи ποявлβнии ποлοсы ποглοщения в диаπазοне часτοτ4. How to use it if you wish to use it in the frequency range
-Τ -Τ-Τ -Τ
1565 см χ - 1595 см иденτиφициρуюτ ρаκ πечени.1565 cm x - 1595 cm identify the liver path.
5. Сποсοб πο π.Ι, ο τ л и ч а ю щ и й с я τем, чτο πρи ποявлении ποлοсы ΠΟΓЛΟЩΘΗИЯ в диаπазοне час- τοτ 2860 см -Τ - 2875 см -Τ иденτиφициρуюτ лимφοгρанулο- маτοз. 5. The method of operation is that, in the event of the occurrence of a broadcasting area at a frequency of 2860 cm-см - 2875 cm, the limb is identified.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/RU1995/000225 WO1997014961A1 (en) | 1995-10-18 | 1995-10-18 | Method of diagnosing malignant disorders |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/RU1995/000225 WO1997014961A1 (en) | 1995-10-18 | 1995-10-18 | Method of diagnosing malignant disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO1997014961A1 true WO1997014961A1 (en) | 1997-04-24 |
Family
ID=20129958
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/RU1995/000225 WO1997014961A1 (en) | 1995-10-18 | 1995-10-18 | Method of diagnosing malignant disorders |
Country Status (1)
| Country | Link |
|---|---|
| WO (1) | WO1997014961A1 (en) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6749565B2 (en) | 2000-07-08 | 2004-06-15 | Victor Chudner | Method for blood infrared spectroscopy diagnosing of inner organs pathology |
| EP1640036A1 (en) * | 2004-09-23 | 2006-03-29 | Heinz Grundmeyer | Bio-energetic diagnostic procedure |
| US9664680B2 (en) | 2012-11-15 | 2017-05-30 | University Of Central Lancashire | Methods of diagnosing proliferative disorders |
| WO2018188763A1 (en) | 2017-04-14 | 2018-10-18 | Cosma S.P.A. | New process for the synthesis of firocoxib |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1992014134A1 (en) * | 1991-02-04 | 1992-08-20 | National Research Council Of Canada | A method of detecting the presence of anomalies in exfoliated cells using infrared spectroscopy |
| US5168162A (en) * | 1991-02-04 | 1992-12-01 | Cornell Research Foundation, Inc. | Method of detecting the presence of anomalies in exfoliated cells using infrared spectroscopy |
| RU2000027C1 (en) * | 1991-12-27 | 1993-02-15 | Галина Петровна Петрова | Method of oncological disease diagnosis |
-
1995
- 1995-10-18 WO PCT/RU1995/000225 patent/WO1997014961A1/en active Application Filing
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1992014134A1 (en) * | 1991-02-04 | 1992-08-20 | National Research Council Of Canada | A method of detecting the presence of anomalies in exfoliated cells using infrared spectroscopy |
| US5168162A (en) * | 1991-02-04 | 1992-12-01 | Cornell Research Foundation, Inc. | Method of detecting the presence of anomalies in exfoliated cells using infrared spectroscopy |
| RU2000027C1 (en) * | 1991-12-27 | 1993-02-15 | Галина Петровна Петрова | Method of oncological disease diagnosis |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6749565B2 (en) | 2000-07-08 | 2004-06-15 | Victor Chudner | Method for blood infrared spectroscopy diagnosing of inner organs pathology |
| EP1640036A1 (en) * | 2004-09-23 | 2006-03-29 | Heinz Grundmeyer | Bio-energetic diagnostic procedure |
| US9664680B2 (en) | 2012-11-15 | 2017-05-30 | University Of Central Lancashire | Methods of diagnosing proliferative disorders |
| US10288615B2 (en) | 2012-11-15 | 2019-05-14 | University Of Central Lancashire | Methods of diagnosing proliferative disorders |
| WO2018188763A1 (en) | 2017-04-14 | 2018-10-18 | Cosma S.P.A. | New process for the synthesis of firocoxib |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP3129956B2 (en) | Device for determining non-invasive body chemistry | |
| ES2712200T3 (en) | Method for measuring a spectral sample response | |
| US4811739A (en) | Method and apparatus for the determination of substances in human fluids | |
| JP3212996B2 (en) | Apparatus for measuring blood glucose level in a living body | |
| US6889069B2 (en) | Non-invasive measurement of blood analytes using photodynamics | |
| Sliwinski et al. | Sensorimotor activity partially ameliorates pain and reduces nociceptive fiber density in the chronically injured spinal cord | |
| CN1555242A (en) | Infrared attenuation total reflection measurement system | |
| JP2000507349A (en) | Non-invasive measurement of optically active compounds | |
| WO2003077756A1 (en) | Physiological method for defining the state of biological tissue (variants) and diagnostic system for carrying out said method | |
| JPH07500030A (en) | Measuring molecular changes in the eye lens | |
| US7209773B2 (en) | Method and apparatus for performing in-vivo blood analysis using raman spectrum | |
| JP2000500374A (en) | Percutaneous measurement of substances in human tissues or fluids | |
| Harris et al. | Emerging eye-based diagnostic technologies for traumatic brain injury | |
| Naumova et al. | Historical review of early researches on mitogenetic radiation: from discovery to cancer diagnostics | |
| WO1997014961A1 (en) | Method of diagnosing malignant disorders | |
| Thomas et al. | Auditory feedback control of vocal pitch in spasmodic dysphonia | |
| Wu et al. | Narrow‐band UVB irradiation stimulates the migration and functional development of vitiligo‐IgG antibodies‐treated pigment cells | |
| WO2000047112A1 (en) | Method for diagnosing proliferation regions and device for realising the same | |
| Chantelau | A novel diagnostic test for end-stage sensory failure associated with diabetic foot ulceration: Proof-of-principle study | |
| Haimid et al. | Helium-Neon Laser Effects on Human Whole Blood by Spectroscopy In vitro Study | |
| JPH09182739A (en) | Measuring apparatus for body fluid component concentration | |
| Fraser-Miller et al. | Can coupling multiple complementary methods improve the spectroscopic based diagnosis of gastrointestinal illnesses? A proof of principle ex vivo study using celiac disease as the model illness | |
| Ono et al. | Local inflammation exacerbates cutaneous manifestations in a murine autoimmune pemphigus model | |
| Motokawa et al. | The relation between the intensity of light and the electrical excitability of the human retina | |
| RU2075059C1 (en) | Process of detection of energy-informative action on tested liquid |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AK | Designated states |
Kind code of ref document: A1 Designated state(s): BY CA CH CN DE DK EE ES FI GB JP KR KZ MX SE UA US |
|
| AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE |
|
| DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
| REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
| NENP | Non-entry into the national phase |
Ref country code: JP Ref document number: 97515723 Format of ref document f/p: F |
|
| 122 | Ep: pct application non-entry in european phase | ||
| NENP | Non-entry into the national phase |
Ref country code: CA |